Covid-19 Update Debate
Full Debate: Read Full DebateDepartment: Department of Health and Social Care
Mark Pawsey
Main Page: Mark Pawsey (Conservative - Rugby)Department Debates - View all Mark Pawsey's debates with the Department of Health and Social Care
(4 years, 1 month ago)
Commons ChamberRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Matt Hancock
That is a very good question from the Chair of the Public Accounts Committee—I would expect nothing less. The critical answer to how long this takes is that it depends on the speed of manufacture in the first instance. My goal, and the goal I have set the NHS, is to be able to roll this out as quickly as it can be manufactured. That manufacturing schedule is uncertain because this is really hard stuff to make. We have got the Major Projects Authority in the Government involved in many of the projects that we have built up in the Department over the past nine months, because I respect its views and its ability to kick the tyres. The roll-out of the vaccine is a huge endeavour, but it builds on the annual roll-out of the flu vaccine—it is just bigger and needs to be done faster.
Mark Pawsey (Rugby) (Con)
The past few months have been a rollercoaster ride for families, businesses and public services as they have tried to make plans for the future. The Secretary of State has rightly spoken of the need for caution about the role of the vaccine, but I think what my constituents would like to hear from him, if he is able to say, is when they can safely start to consider family events and holidays and when businesses will be able to get back to something like business as usual.
Matt Hancock
I understand the yearning for certainty. All I can say to my hon. Friend, in honesty, is that I want us to get back to normal as quickly as possible, and yesterday’s news is a big step forward, but it is not the only step. There are more steps that are needed. The scientists are now offering views on that sort of timetable, but the Government’s view is that we must make this happen as quickly as possible and be ready to roll out as fast as any safe vaccine can be manufactured, but we will not put safety at risk. That is a lodestar of the programme and therefore we have to await the clinical safety sign-off before we can take this to the next stage.